INDO BORAX & CHEMICALS LIMITED
CIN: L24100MH1980PLC023177
Regd. Office: 506, 5th Floor, Tulsiani Chambers, Free Press Journal Marg, Nariman Point, Mumbai-400021, Tel: 022-35218591, email: info@indoborax.com
Corp. Office : 201-A, Vedanta, 779A, Makwana Road, Marol Village, Andheri (E), Mumbai:400 059

Date: **11th November, 2026**

To, **BSE Limited,** **Corporate Relationship Department,** Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 **Stock Code: 524342**	To, **National Stock Exchange of India Ltd,** **Listing Department,** Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 **Stock Code: INDOBORAX**

Dear Sir / Madam,

Subject: Press Release on Un-Audited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2026

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on the Un-Audited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2026.

We request you to kindly take the same on record.

Thanking you.

For Indo Borax & Chemicals Limited

PRAVIN PRABHAKAR CHAVAN

Digitally signed by PRAVIN PRABHAKAR CHAVAN
Date: 2026.11.11 13:52:35 +05'30'

Pravin Chavan
Company Secretary & Compliance Officer
Membership No.: A16857

Encl: As above

Indo Borax & Chemicals Ltd.

Indo Borax H1FY27 Consolidated Operating Income up 16.0% to Rs 129.29 crore; Adjusted EBITDA up 22.9%

- *Consolidated Adjusted EBITDA for H1FY27 stood at Rs. 28.09 crore, while the Adjusted EBITDA margin stood at 21.7%*
- *Company completes its acquisition of 64.26% stake in Kronox Lab Sciences Ltd and appoints Mr. Suresh Kalra as Managing Director and Chief Executive Officer at Kronox*
- *Received Board approval for amalgamation of its wholly owned subsidiary – Indoborax Infrastructure Private Ltd with Indo Borax Chemicals, subject to necessary regulatory approvals*

Mumbai, November 11, 2026: Indo Borax & Chemicals Ltd (BSE: 524342; NSE: INDOBORAX), one of India's leading manufacturers of boron-based chemicals, posted 16.0% growth in consolidated operating income for H1FY27 to Rs. 129.29 crore, up from Rs. 111.42 crore in H1FY26. The company's consolidated Profit After Tax for H1FY27 stood at Rs. 21.00 crore, compared to Rs. 26.47 crore. The company's Adjusted EBITDA and PAT margins (both on a consolidated basis) for H1FY27 stood at 21.7% and 15.4%, respectively.

Consolidated Financial Highlights (Rs. Crore)

Particulars	Q2 FY27	Q2 FY26	Growth (%)	H1 FY27	H1 FY26	Growth (%)
Operating Income	**58.94**	**57.85**	**1.9**	**129.29**	**111.42**	**16**
Total Income	63.35	61.42	**3.1**	136.26	118.01	**15.5**
EBITDA	**1.48**	**10.5**	(85.9)	**21.28**	**22.71**	(6.3)
EBITDA Margin (%)	2.5	18.2		16.5	20.4	
***Adjusted EBITDA**	**7.93**	**10.58**	(25.0)	**28.09**	**22.85**	**22.9**
*Adjusted EBITDA Margin (%)	13.5	18.3		21.7	20.5	
PAT	**4.75**	**16.26**	(70.8)	**21**	**26.47**	(20.7)
PAT Margin (%)	7.5	26.5		15.4	22.4	
EPS (Rs.)	1.47	5.07	(71.0)	6.54	8.25	(20.7)

**** Adjusted EBITDA = EBITDA (+) ESOP expense (+) Forex gain***

For Q2FY27, the company's Consolidated Operating income stood at Rs 58.94 crore, compared to Rs 57.85 crore in Q2FY26. Consolidated EBITDA for Q2 FY27 stood at Rs 7.93 crore, while PAT stood at Rs 4.75 crore. EBITDA margin came under pressure due to high raw material costs in the quarter, driven by global supply chain challenges. The company's PAT margin in Q2 FY27 was net of expenses of Rs 6.64 crore, related to the acquisition of Kronox Lab Sciences Ltd as a subsidiary.

Indo Borax & Chemicals Ltd.

Commenting on the company's performance during the quarter, **Mr. Suresh Kalra, Managing Director & CEO, Indo Borax & Chemicals Ltd.**, said, "The quarter under review witnessed steady demand across our key product segments, despite the seasonal impact of the monsoon. However, profitability remained under pressure due to higher raw material costs and geopolitical uncertainties in the Middle East, thereby impacting the overall cost environment. We will continue to focus on operational efficiencies, prudent cost management and optimising product mix to navigate these challenges in the coming quarters.

"The quarter under review also witnessed strategic integration and stabilisation of synergies with the recently acquired Kronox Lab Sciences, in terms of markets of distribution and procurement ecosystem. Going forward, we are confident of sustaining the growth momentum and strengthening our margins further, backed by diversification, premiumisation and disciplined execution", further added **Mr. Kalra**.

The company has also recently received Board approval to amalgamate its wholly owned subsidiary, Indoborax Infrastructure Private Ltd, with Indo Borax Chemicals. This will be subject to necessary approvals from NCLT and other regulatory authorities.

"We expect the proposed amalgamation to unlock greater operational efficiencies by enabling the pooling and optimal utilisation of resources across the combined entity. It will also facilitate sharper management focus, simplify governance structures and enable more agile decision-making, thereby creating a more integrated and efficient organisation," **Mr. Kalra** said.

About Indo Borax & Chemicals Ltd.

Indo Borax & Chemicals Ltd., established in 1980, is India's leading manufacturer of boron-based chemicals and the industry benchmark for Boric Acid. Being the only company to hold a Food and Drug Administration (FDA) license for manufacturing Pharma Grade Boric Acid as per the Indian Pharmacopoeia, Indo Borax operates the most modern Boric Acid, Disodium Octaborate Tetrahydrate (D.O.T.), and Borax plant in Pithampur, Madhya Pradesh. It was also the first company in India to receive a BIS license for manufacturing Technical Grade Boric Acid.

Backed by over 28,000 shareholders, Indo Borax was featured in Forbes Asia Pacific's Top 200 Under A Billion Dollar Public Companies (2023) and recognised by The Economic Times for its value-driven growth approach.

For Media Queries	Deepali Shah	90295 57708	deepali@fortunapr.com
For IR Queries	Rajshree Ganguly	98338 07235	rajshree@fortunapr.com